Sharabi Y, Sachs D H
Transplantation Biology Section, National Cancer Institute, Bethesda, Maryland 20892.
J Exp Med. 1989 Feb 1;169(2):493-502. doi: 10.1084/jem.169.2.493.
The use of allogeneic bone marrow transplantation as a means of inducing donor-specific tolerance across MHC barriers could provide an immunologically specific conditioning regimen for organ transplantation. However, a major limitation to this approach is the toxicity of whole body irradiation as currently used to abrogate host resistance and permit marrow engraftment. The present study describes methodology for abrogating host resistance and permitting marrow engraftment without lethal irradiation. Our preparative protocol involves administration of anti-CD4 and anti-CD8 mAbs in vivo, 300-rad WBI, 700-rad thymic irradiation, and unmanipulated fully MHC-disparate bone marrow. B10 mice prepared by this regimen developed stable mixed lymphohematopoetic chimerism without any clinical evidence of graft-vs.-host disease. Engraftment was accompanied by induction of specific tolerance to donor skin grafts (B10.D2), while third-party skin grafts (B10.BR) were promptly rejected. Mice treated with the complete regimen without bone marrow transplantation appeared healthy and enjoyed long-term survival. This study therefore demonstrates that stable mixed chimerism with donor-specific tolerance can be induced across an MHC barrier after a nonlethal preparative regimen, without clinical GVHD and without the risk of aplasia.
将同种异体骨髓移植作为一种跨越主要组织相容性复合体(MHC)屏障诱导供体特异性耐受的手段,可为器官移植提供一种免疫特异性预处理方案。然而,这种方法的一个主要局限是目前用于消除宿主抵抗力并允许骨髓植入的全身照射的毒性。本研究描述了在不进行致死性照射的情况下消除宿主抵抗力并允许骨髓植入的方法。我们的预处理方案包括在体内给予抗CD4和抗CD8单克隆抗体、300拉德的全身照射、700拉德的胸腺照射以及未处理的完全MHC不相合的骨髓。通过该方案制备的B10小鼠形成了稳定的混合淋巴细胞造血嵌合体,且没有任何移植物抗宿主病的临床证据。植入伴随着对供体皮肤移植物(B10.D2)特异性耐受的诱导,而第三方皮肤移植物(B10.BR)则被迅速排斥。接受完整方案但未进行骨髓移植治疗的小鼠看起来健康并长期存活。因此,本研究表明,在非致死性预处理方案后,可以跨越MHC屏障诱导出具有供体特异性耐受的稳定混合嵌合体,且无临床移植物抗宿主病,也无再生障碍风险。